<DOC>
	<DOCNO>NCT01396707</DOCNO>
	<brief_summary>This open-label , multicentre , prospective phase II trial design evaluate efficacy safety trastuzumab combination capecitabine oxaliplatin first-line therapy patient recurrent and/or metastatic HER2 positive adenocarcinoma stomach gastro-oesophageal junction .</brief_summary>
	<brief_title>Trastuzumab Combination With Capecitabine Oxaliplatin ( XELOX ) Patients With Advanced Gastric Cancer ( AGC )</brief_title>
	<detailed_description>Patients administer 6 cycle combination chemotherapy , unless withdraw earlier due unacceptable toxicity , disease progression , consent withdrawal . Patients continue treat trastuzumab alone disease progression , unacceptable toxicity consent withdrawal finish maximum 6 cycle combination chemotherapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma stomach gastrooesophageal junction inoperable locally advanced recurrent and/or metastatic disease , amenable curative therapy . 2 . Measurable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST ) , assess use image technique ( CT MRI ) . 3 . HER2 positive tumour ( primary tumour metastasis ) define either IHC2+ FISH+ IHC3+ accord gastric cancer score system HER2 4 . ECOG Performance status 0 , 1 2 5 . Life expectancy least 3 month . 6 . Male female . Age 20 year . 7 . Signed informed consent . 1 . Previous chemotherapy advanced/metastatic disease ( prior adjuvant/neoadjuvant therapy allow least 6 month elapse completion adjuvant/neoadjuvant therapy enrolment study ; adjuvant/neoadjuvant therapy platinum allow ) . 2 . Lack physical integrity upper gastrointestinal tract malabsorption syndrome ( e.g . patient partial total gastrectomy enter study , jejunostomy tube ) . 3 . Patients active ( significant uncontrolled ) gastrointestinal bleeding . 4 . Residual relevant toxicity result previous therapy ( exception alopecia ) , e.g . neurological toxicity grade 2 NCICTCAE . 5 . Other malignancy within last 5 year , except carcinoma situ cervix , basal cell carcinoma . 6 . Neutrophil count &lt; 1.5 × 109/L , platelet count &lt; 100 × 109/L . 7 . Serum bilirubin &gt; 1.5 × upper limit normal ( ULN ) ; , AST ALT &gt; 2.5 × ULN ( &gt; 5 × ULN patient liver metastasis ) ; , alkaline phosphatase &gt; 2.5 × ULN ( &gt; 5 × ULN patient liver metastasis , &gt; 10 × ULN patient bone liver metastasis ) ; , albumin &lt; 25 g/L . 8 . Creatinine clearance &lt; 60 mL/min . Other Study DrugRelated Exclusion Criteria 9 . History document congestive heart failure ; angina pectoris require medication ; evidence transmural myocardial infarction ECG ; poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) ; clinically significant valvular heart disease ; high risk uncontrollable arrhythmia . 10 . Baseline LVEF &lt; 50 % ( measure echocardiography MUGA ) . 11 . Patients dyspnea rest due complication advance malignancy disease , require supportive oxygen therapy . 12 . Patients receive chronic high dose corticosteroid therapy . ( Inhaled steroid short course oral steroid antiemesis appetite stimulant allow ) . 13 . Clinically significant hearing abnormality . 14 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . 15 . History clinical evidence brain metastasis . 16 . Serious uncontrolled systemic intercurrent illness , e.g . infection poorly control diabetes . 17 . Positive serum pregnancy test woman childbearing potential . 18 . Subjects reproductive potential willing use effective method contraception . 19 . Received investigational drug treatment within 4 week start study treatment . 20 . Radiotherapy within 4 week start study treatment ( 2 week interval allow palliative radiotherapy give bone metastatic site peripherally patient recover acute toxicity ) . 21 . Major surgery within 4 week start study treatment , without complete recovery . 22 . History HIV infection , Patients know active infection HBV , HCV . 23 . Known hypersensitivity study drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HER2</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>XELOX</keyword>
	<keyword>PHASE 2</keyword>
</DOC>